Drug Profile
Peptide YY - Novo Nordisk
Alternative Names: NC01651562; NNC 0165 1562Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Hormones; Obesity therapies; Peptides
- Mechanism of Action Peptide YY replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Obesity(Combination therapy) in USA (SC, Injection)
- 27 Jul 2019 Novo Nordisk completes a phase I trial in Obesity in USA (NCT03574584)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)